• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Development of myeloid neoplasia associated with prolonged immune cell-associated hematotoxicity after CAR T-cell treatment of B-cell lymphoma: Should we surveille for pre-existing myeloid mutations?

作者信息

Carlsten Mattias, Lindfors Rossi Elisa Linnea, Jädersten Martin, Tesi Bianca, Abd Own Sulaf, Sander Brigitta, Deneberg Stefan, Ivinskiy Anne, Sonnevi Kristina, Sjölund Hanna, Enblad Gunilla, Wahlin Björn, Mielke Stephan

机构信息

Department of Cell Therapy and Allogenic Stem Cell Transplantation Karolinska Comprehensive Cancer Center and ATMP Center, Karolinska University Hospital Stockholm Sweden.

Biomolecular and Cellular Medicine, Department of Laboratory Medicine Karolinska Institutet Stockholm Sweden.

出版信息

Hemasphere. 2025 Jun 5;9(6):e70160. doi: 10.1002/hem3.70160. eCollection 2025 Jun.

DOI:10.1002/hem3.70160
PMID:40476183
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12138822/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f54/12138822/0272d0961dc2/HEM3-9-e70160-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f54/12138822/0272d0961dc2/HEM3-9-e70160-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f54/12138822/0272d0961dc2/HEM3-9-e70160-g001.jpg

相似文献

1
Development of myeloid neoplasia associated with prolonged immune cell-associated hematotoxicity after CAR T-cell treatment of B-cell lymphoma: Should we surveille for pre-existing myeloid mutations?CAR-T细胞治疗B细胞淋巴瘤后与长期免疫细胞相关血液毒性相关的髓系肿瘤的发生：我们应该监测是否存在预先存在的髓系突变吗？
Hemasphere. 2025 Jun 5;9(6):e70160. doi: 10.1002/hem3.70160. eCollection 2025 Jun.
2
Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia.全血细胞毒性的发展：预测B细胞急性淋巴细胞白血病中CAR T细胞治疗后的血液毒性
Blood. 2025 Mar 13;145(11):1136-1148. doi: 10.1182/blood.2024025910.
3
Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.嵌合抗原受体 T 细胞（CAR T）治疗难治/复发 B 细胞淋巴瘤后发生的继发性髓系肿瘤：病例系列及文献复习。
Front Immunol. 2023 Jan 13;13:1063986. doi: 10.3389/fimmu.2022.1063986. eCollection 2022.
4
Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model.嵌合抗原受体 T 细胞治疗后细胞因子释放综合征对长期血液学毒性的临床影响：Kyoto 评分，一种新的预测模型。
Transplant Cell Ther. 2024 Apr;30(4):404-414. doi: 10.1016/j.jtct.2024.01.073. Epub 2024 Jan 26.
5
Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy.克隆性造血与嵌合抗原受体 T 细胞（CART）治疗患者的严重细胞因子释放综合征相关。
Transplant Cell Ther. 2024 Sep;30(9):927.e1-927.e9. doi: 10.1016/j.jtct.2024.06.008. Epub 2024 Jun 11.
6
The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy.CD19嵌合抗原受体T细胞疗法后血液毒性的危险因素及早期预测模型
Front Oncol. 2022 Sep 30;12:987965. doi: 10.3389/fonc.2022.987965. eCollection 2022.
7
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.嵌合抗原受体 T 细胞相关血液学毒性：复发/难治性大 B 细胞淋巴瘤中嵌合抗原受体 T 细胞相关血液学毒性的模型。
Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543.
8
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors.白血病、淋巴瘤和实体瘤患者接受免疫效应细胞治疗和淋巴细胞耗竭后细胞持续减少。
Cytotherapy. 2024 Sep;26(9):1026-1032. doi: 10.1016/j.jcyt.2024.04.075. Epub 2024 May 8.
9
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.CD19 CAR-T 治疗后严重的血液毒性与抑制性免疫失调和有限的 CAR-T 扩增有关。
Sci Adv. 2023 Sep 22;9(38):eadg3919. doi: 10.1126/sciadv.adg3919.
10
Mechanisms and management of CAR T toxicity.嵌合抗原受体T细胞毒性的机制与管理
Front Oncol. 2024 May 21;14:1396490. doi: 10.3389/fonc.2024.1396490. eCollection 2024.

引用本文的文献

1
Acute myeloid leukemia after CAR T-cell therapy: role of pre-existing clonal hematopoiesis and inflammation in leukemogenesis.嵌合抗原受体T细胞疗法后发生的急性髓系白血病：既往存在的克隆性造血和炎症在白血病发生中的作用
Bone Marrow Transplant. 2025 Aug 21. doi: 10.1038/s41409-025-02700-4.

本文引用的文献

1
Characteristics of second primary malignancies following bispecific antibodies therapy.双特异性抗体治疗后第二原发性恶性肿瘤的特征。
J Immunother Cancer. 2025 Apr 5;13(4):e011200. doi: 10.1136/jitc-2024-011200.
2
Implementation of standard of care CAR-T-cell treatment for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia in Sweden.瑞典针对侵袭性B细胞淋巴瘤和急性淋巴细胞白血病患者实施嵌合抗原受体T细胞（CAR-T）治疗的护理标准。
Leukemia. 2025 May;39(5):1256-1259. doi: 10.1038/s41375-025-02573-y. Epub 2025 Mar 26.
3
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody.
抗BCMA嵌合抗原受体T细胞和GPRC5D导向双特异性抗体治疗后T细胞淋巴瘤的多组学分析
Nat Med. 2025 Apr;31(4):1145-1153. doi: 10.1038/s41591-025-03499-9. Epub 2025 Feb 21.
4
Hemophagocytic Lymphohistiocytosis.噬血细胞性淋巴组织细胞增生症
N Engl J Med. 2025 Feb 6;392(6):584-598. doi: 10.1056/NEJMra2314005.
5
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.嵌合抗原受体 T 细胞治疗后非复发死亡率的系统评价和荟萃分析。
Nat Med. 2024 Sep;30(9):2667-2678. doi: 10.1038/s41591-024-03084-6. Epub 2024 Jul 8.
6
Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study.淋巴瘤中CD-19导向的嵌合抗原受体T细胞疗法后的继发性原发性恶性肿瘤：来自意大利CART-SIE研究的报告。
Br J Haematol. 2024 Oct;205(4):1356-1360. doi: 10.1111/bjh.19590. Epub 2024 Jun 15.
7
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.免疫效应细胞相关血液学毒性：EHA/EBMT 共识分级和最佳实践建议。
Blood. 2023 Sep 7;142(10):865-877. doi: 10.1182/blood.2023020578.
8
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.ZUMA-1 的 5 年随访结果支持 axi-cel 在难治性大 B 细胞淋巴瘤中的治疗潜力。
Blood. 2023 May 11;141(19):2307-2315. doi: 10.1182/blood.2022018893.
9
Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis.自体抗 CD19 嵌合抗原受体 T 细胞治疗复发或难治性 B 细胞急性淋巴细胞白血病的长期疗效：系统评价和荟萃分析。
Cancer Gene Ther. 2023 Jun;30(6):845-854. doi: 10.1038/s41417-023-00593-3. Epub 2023 Feb 7.
10
Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.嵌合抗原受体 T 细胞（CAR T）治疗难治/复发 B 细胞淋巴瘤后发生的继发性髓系肿瘤：病例系列及文献复习。
Front Immunol. 2023 Jan 13;13:1063986. doi: 10.3389/fimmu.2022.1063986. eCollection 2022.